Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

Novel sensor measures individual particles in blood samples

Norwegian researchers have developed the world's first sensor capable of measuring individual particles in a blood sample. This new innovation could cause a sensation in the medical world.

7 Dec 2012

Diabetes drug may improve ovarian cancer survival

Women with ovarian cancer who are also receiving metformin for diabetes have significantly improved survival rates compared with their counterparts without diabetes, study findings show.

7 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

Metformin improves survival in diabetic patients with ovarian cancer

Diabetic patients with ovarian cancer who took the drug metformin for their diabetes had a better survival rate than patients who did not take it, a study headed by Mayo Clinic shows. The findings, published early online in the journal Cancer, may play an important role for researchers as they study the use of existing medications to treat different or new diseases.

3 Dec 2012

Vermillion’s OVA1 diagnostic test effectively identifies early-stage ovarian cancer

Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1 which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer.

29 Nov 2012

Contralateral prophylactic mastectomy does not reduce breast cancer recurrence

About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds.

28 Nov 2012

Viral Genetics changes name to VG Life Sciences

Viral Genetics, Inc. today announced that it has changed its name to VG Life Sciences Inc. and that it has completed its 1-for-600 reverse stock split, both of which will take effect at the open of trading on November 27, 2012.

26 Nov 2012

MicroRNAs in ovarian cancer cells promote tumor growth

Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.

22 Nov 2012

Viruses to treat metastatic cancers

There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?

15 Nov 2012

Women with ovarian cancer have superior outcomes after surgery at high-volume hospitals

A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.

9 Nov 2012

Ion AmpliSeq Community Panels from Life Technologies

Life Technologies Corporation today announced Ion AmpliSeq Community Panels, a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.

7 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites).

30 Oct 2012

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer.

25 Oct 2012

Study to examine possible link between mitochondrial DNA and ovarian cancer

Ovarian cancer is a deadly disease. With no overt symptoms and no screening tests to catch it early, ovarian cancer is often detected at stage 3 or later. By then, it can be very aggressive and may have spread beyond the ovaries into other organs. Many women eventually succumb to it; the five-year survival rate for a stage 3 ovarian cancer diagnosis is only 34 percent.

24 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

New research lists cell stiffness as possible biomarker for metastatic ovarian cancer

New Georgia Tech research shows that cell stiffness could be a valuable clue for doctors as they search for and treat cancerous cells before they're able to spread. The findings, which are published in the journal PLoS One, found that highly metastatic ovarian cancer cells are several times softer than less metastatic ovarian cancer cells.

11 Oct 2012

Aspirin associated with reduced risk of serious ovarian cancer

New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serious ovarian cancer—an aggressive carcinoma affecting the surface of the ovary.

10 Oct 2012